子宫切除术与子宫悬吊术式原生组织顶端脱垂手术后的再手术治疗比较
这项回顾性队列研究利用2010至2019年Medicare 5%限定数据集,纳入2341例65岁及以上子宫阴道脱垂患者,比较子宫悬吊术(584例)与同期子宫切除术(1757例)后因脱垂再次手术的风险。5年时子宫悬吊组再手术率为9.1%,子宫切除组为6.7%(P=.07);
要点
- 5年因脱垂再手术率子宫悬吊组9.1% vs 子宫切除组6.7%,未达统计学显著(P=.07)。
- 子宫悬吊组术后5年内因后续子宫切除术的比例为3.4%(n=14)。
核心结论
- 在Medicare数据库中,原生组织脱垂手术时行子宫悬吊术者因脱垂再手术的风险高于同期行子宫切除术者,但绝对差异较小。
- 子宫悬吊术后5年内约3%的患者需行子宫切除术。
研究设计与样本
- 回顾性队列研究,使用2010至2019年Medicare 5%限定数据集。
- 纳入65岁及以上诊断为子宫阴道脱垂并接受顶端原生组织脱垂手术(腹膜外或腹膜内阴道穹窿悬吊)的女性患者。
- 排除经阴道网片、同期结直肠或肿瘤手术、闭塞性手术及经腹子宫切除术者。
- 共纳入2341例,其中子宫悬吊组584例,子宫切除组1757例;随访自索引手术至死亡或失访。
主要发现
- 子宫悬吊组患者年龄更大(73.4岁 vs 71.8岁,P<.001),主要位于南部(46.2% vs 34.1%,P<.001),Charlson合并症指数均值更高(1.6 vs 1.3,P=.003)。
- 5年时因子宫阴道脱垂再手术率子宫悬吊组为9.1%(n=40),子宫切除组为6.7%(n=91),P=.07。
- 子宫悬吊组索引手术后5年内后续子宫切除术率为3.4%(n=14)。
- 按腹膜内(n=120)或腹膜外(n=464)子宫悬吊分层,两种顶端悬吊方式的再手术率无显著差异(P=.49)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interest in uterine-sparing procedures has increased due to the potential for lower blood loss and shorter operative time. Surgical efficacy of hysteropexy relative to traditional hysterectomy-based prolapse procedure remains uncertain over the long-term. OBJECTIVE: The objective of our study was to determine if there is a difference in the rate of surgical retreatment for prolapse after native-tissue apical prolapse surgery with hysterectomy vs uterine preservation. STUDY DESIGN: This was a retrospective cohort study utilizing the Medicare 5% Limited Data Set from 2010 to 2019. We included all female patients aged 65 years or older with a diagnosis of uterovaginal prolapse who underwent an apical native-tissue prolapse procedure (extraperitoneal or intraperitoneal colpopexy). We excluded those with transvaginal mesh, concurrent colorectal or oncologic surgeries, obliterative procedures, and abdominal hysterectomies. All patients were followed from the index procedure until death or loss to follow-up. We compared those who had a hysteropexy vs those who underwent a concurrent vaginal or minimally invasive hysterectomy. The primary outcome was surgical retreatment for pelvic organ prolapse defined as any subsequent surgical treatment of anterior, apical, or posterior compartment prolapse after the index surgery. Time-to-event analysis was performed, and the 2 groups were compared using Cox regression analysis adjusting for covariates. RESULTS: We identified 2341 patients who met inclusion and exclusion criteria (hysteropexy = 584 vs hysterectomy = 1757). Patients in the hysteropexy group were older (73.4 vs 71.8 years, P<.001) and predominantly located in the South (46.2% vs 34.1%, P<.001). The mean Charlson comorbidity index score was higher for hysteropexy patients (1.6 vs 1.3, P=.003). At 5 years, 9.1% (n=40) had surgical retreatment for prolapse in the hysteropexy group compared to 6.7% (n=91) for the hysterectomy group (P=.07). With adjustment for age, Charlson Comorbidity Index, Dual Medicare/Medicaid status, race, and region, those with a hysteropexy had higher risk of surgical retreatment than those with a hysterectomy (adjusted odds ratio 1.52,1.04-2.21, P=.03). For those in the hysteropexy group, the rate of subsequent hysterectomy in the 5 years following index surgery was 3.4% (n=14). When stratified by intraperitoneal (n=120) or extraperitoneal hysteropexy (n=464), there were no significant differences in rates of surgical retreatment between the 2 modes of apical suspension (P=.49). The composite rate of surgical retreatment including prolapse retreatment or hysterectomy or uterine/cervical related procedures was 42 (9.7%) for the hysteropexy group and 94 (7.0%) for the hysterectomy group (P=.049) CONCLUSION: In this Medicare database, there was a higher risk of surgical retreatment for prolapse in those who had a hysteropexy compared to those who had a hysterectomy at the time of native-tissue prolapse surgery though the absolute difference is small. For those who had a hysteropexy, 3% of patients required a hysterectomy in the 5 years following index surgery.
引用
- Chang OH, Ford C, Wu JM, et al. Surgical retreatment after native-tissue apical prolapse surgery with hysterectomy vs hysteropexy. Am J Obstet Gynecol. 2025. PMID: 40064410. doi:10.1016/j.ajog.2025.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。